AUSTIN, Texas—Breyer Capital, a leading global investment firm dedicated to backing high-impact entrepreneurs, has announced the appointment of Morgan Cheatham as a Partner and Head of Healthcare and Life Sciences. In his new role, Cheatham will spearhead the firm's early-stage investments in healthcare and life sciences, focusing on cutting-edge biomedical technologies and innovative models of care. He will collaborate closely with Breyer Capital's founder, Jim Breyer, and the firm’s healthcare and life sciences portfolio companies, including OpenEvidence, Artera, Arena Bioworks, Atropos Health, Cleerly, Iterative Health, Slope, and SandboxAQ. Cheatham joins Breyer Capital from Bessemer Venture Partners, where he served as a Vice President, concentrating on healthcare and life sciences investments across various sectors such as software, services, therapeutics, and diagnostics. He was instrumental in shaping Bessemer's investment thesis in healthcare AI and sourced over a dozen early-stage investments. Notable among these are Abridge and Hinge Health, both of which have since grown into multi-billion-dollar companies that define their respective categories. Additionally, Cheatham helped incubate and launch a cardiology business and served as the interim CEO of a rapidly growing telemedicine company. He also played a crucial role in Bessemer’s biotech practice, partnering with startups like Seismic Therapeutics, and co-founded Decoding Bio, a digital platform exploring the future of AI and biotech. Recognized for his achievements, Cheatham was named to Forbes' 30 Under 30 list for Venture Capital in 2023. Despite his transition to Breyer Capital, he will continue his roles as part of the Editorial Team at NEJM AI and as a Clinical Fellow in Genomics at Harvard. "We are thrilled to welcome Morgan to Breyer Capital," said Jim Breyer, the firm’s founder. "Morgan brings a proven track record in healthcare and life sciences investing, deep sector knowledge, and a robust network of innovators. His passion for advancing technologies that enhance lives aligns perfectly with our mission, whether through groundbreaking biomedical research or new models of care that transform patient experiences. We are excited about the positive impact he will have on our portfolio and the wider healthcare industry." "Scientific and technological advancements are moving faster than the evolution of healthcare delivery," Cheatham noted. "The next generation of healthcare and life sciences will emerge from the intersection of innovative discoveries, critical clinical needs, and significant institutional changes. I am eager to build on Breyer Capital's strong reputation for supporting visionaries at this crucial juncture and to invest in teams that are reimagining healthcare to tackle the most pressing challenges of our time." About Breyer Capital Founded by renowned investor Jim Breyer in 2006, Breyer Capital is a top-tier venture capital and private equity firm focused on fostering high-impact entrepreneurs. The firm makes long-term, strategic investments in areas such as artificial intelligence, healthcare, life sciences, enterprise, consumer, and financial technologies. Breyer Capital is known for its willingness to experiment, aiming to achieve breakthrough performance and partner with founders and teams passionate about creating transformative, technology-driven companies. For more information, visit www.breyercapital.com.